Piet Moerman Email & Phone Number

Gent Area, Belgium

Consulting. Identifying and developing products and business opportunities in the field of medical diagnostics.

Belgium

Product portfolio development of novel self-monitoring devices to improve the clinical outcomes in diabetes patients.• Conception and development 2 new products for diabetes self-monitoring. For two distinct markets: testing C-peptide for the (pre)diabetes markets and Insulin testing for the T1 diabetes market.• Market research and product concept testing with consumers and KOL’s. • Identified and contracted partner with enabling technologies for low cost self-monitoring. Product requirements. Prototypes are now available for clinical testing.• Design and funding of 2 pivotal clinical trials for these products

Belgium

Responsible for the identification and subsequent clinical validation of marketable clinical applications of novel biomarkers generated by Pronota’s technology engine.• Defined clinical application for 2 novel heart failure markers, filling currently unmet clinical needs (volume overload and improvement of BNP performance). Filed relevant patents applications.• Developed and implemented a clinical validation program with key opinion leaders. Primary focus was on validating volume overload marker in heart failure patients. Results partially published.• Specified clinical applications for biomarkers for predicting pulmonary mortality, pre-eclampsia and ischemia. 3 patents filed.Pronota NV has been acquired by BioCartis NV and spun of as MyCartis NV.

Gent, Belgium

Company developed the combined use of glucose and ketones to predict hypo- and hyperglycemia in type I diabetes. In 2011 the IP was sold to Abbott Diabetes Care. The United States Patent 8,718,943 was granted on May 6, 2014: Method and device for utilizing analyte levels to assist in the treatment of diabetes.

Stirling - Scotland

Upstream marketing and product development for a BNP monitor for home use. Market development analysis for this novel product concept.• Drove the development of the marketing spec (consumer needs, price points, functionality)• Designed the clinical validation program from proof of concept, algorithm development, and algorithm validation up to PMA submission study.• Leading a cross functional team.• Drove the development of the Product requirement specification.

Gent Belgium

During a 3 year lock-out period after the acquisition of Alere's diabetes division by JNJ, I ran a start up in metabolic monitoring (ketones – FFA’s) for weight loss applications. The Company was acquired by Alere in 2004.

Boston, Usa

P&L and new product development responsibility for retail marketing, US division as well as product pipeline development.• Rejuvenated tired vitamin range (protrega, Stresstabs) and introduced new herbal line resulting in additional 5 SKU’s in all major drugstore chains in 2 years time. Reduced manufacturing cost with 30% by increasing sales volume through supplying both the ‘branded’ and the ‘generic’ Stresstabs.• Developed wireless diabetes concept.• Developed and designed the various glucose monitors for JNJ (Alere’s main customer)

Gent, Belgium

P&L and new product development responsibility for consumer marketing in Europe as well as product pipeline development.• Set up European sales and marketing organization for fertility testing and generic glucose strips. Realised 20 mio$ turnover by 1997.• Designed One Touch Ultra (now sold by JNJ) This product won “best product of the year award” by Consumer Report, twice.• Product development work for Home HIV testing. Presented the epidemiological case for HIV home testing to the Department of Health in the UK.

Utrecht - Netherlands, Antwerp - Belgium, Strassbourg - France

Successful launch of the first glucose biosensor for home monitoring by diabetics in Europe. Product spec production for various other diganostics.

Md, Medecine

Medical Doctor

Marketing

Marketing course